Have £5,000 to invest? I’d buy these 2 FTSE 100 growth stocks

These FTSE 100 growth stocks are beating the market. Roland Head explains why he expects these big-cap winners to deliver further gains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 is often associated with huge, mature businesses that pay dividends but deliver very little growth. Today I want to get away from that cliché and look at two terrific growth stocks that have made it into the blue-chip index.

Both of my picks have delivered double-digit share price gains over the last two years — the FTSE 100 has fallen by around 15% over the same period.

Growth stock #1: a pharma play

Hikma Pharmaceuticals (LSE: HIK) has been a top performer so far this year, rising by around 20% in five months. Although pharmaceutical firms have benefited from extra investor interest due to the coronavirus pandemic, I believe Hikma is a genuine growth stock, with solid profits and good prospects.

The group’s business is centred around producing injectable medicines and generic versions of branded products that have lost their patent protection. It’s a very profitable business, with an operating margin of 24% in 2019.

Cash generation is also strong and unlike some larger pharma groups, Hikma doesn’t rely on borrowed cash. Net debt was just $242m at the end of 2019, giving a leverage multiple of just 0.4x EBITDA. In plain English, that’s very low.

Why I’d buy

City forecasts suggest that Hikma’s profits will rise by around 8% this year, with a 10% increase pencilled in for 2021.

The firm’s shares are currently trading close to all-time highs, leaving them with a 2020 forecast price/earnings ratio of around 18. That may not seem cheap, but it’s actually well below the UK pharmaceutical sector average P/E of 30.

Profits are expected to rise by a further 10% in 2021. I see the firm as a growth stock to buy at current levels.

Growth stock #2: my bet on UK property

The UK housing market might not seem like the safest investment at the moment. But I think my next pick is an essential service that estate agents can’t live without — even in a downturn.

Property listing website Rightmove (LSE: RMV) dominates the UK market, leaving rivals Zoopla and OnTheMarket.com trailing in the distance. According to the firm, it had a market share of over 75% in 2019, based on the time spent browsing the top four UK property websites.

This dominance gives Rightmove a lot of pricing power. The company generated an operating profit of £214m on revenue of £289m last year. That’s equivalent to a profit margin of 74%. It’s not hard to see why this has been such a successful growth stock — the Rightmove share price has risen by nearly 40% over the last 18 months.

A long-term winner?

Estate agents tend to complain about Rightmove’s pricing. Some big estate agency groups even clubbed together to launch a rival, OnTheMarket.com.

I have some sympathy with the estate agents’ complaints. But Rightmove is expanding steadily into the letting sector and now also lists new homes. In reality, I believe this website will continue to be an essential part of most estate agents’ businesses.

Rightmove has cut its fees by 75% for the period from April to July this year. 2020 profits will be down. But analysts expect earnings to bounce back next year — a view I share.

The latest forecasts put Rightmove stock on a price/earnings ratio of 30 for 2021. For such a dominant and profitable business, I think this could be a good buy.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Rightmove. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand flipping wooden cubes for change wording" Panic" to " Calm".
Investing Articles

The S&P 500 looks ominous right now, but…

A glance at the S&P 500’s current valuation makes it look like a stock market crash might be coming. But…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Here’s why Experian, RELX, and LSEG just crashed up to 16% in the FTSE 100

Software stocks across the FTSE 100 index got absolutely hammered today. What on earth has happened to cause this sudden…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Is it worth looking for stocks to buy with just £100?

Is what a Cockney calls a 'ton' enough to start investing? Or do you need a tonne of money to…

Read more »

National Grid engineers at a substation
Investing Articles

Should an income-focused investor consider National Grid shares?

One attraction of National Grid shares for many investors is the company's dividend strategy. Our writer explores some pros and…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Want to retire early? Here’s how a stock market crash could help!

Many people fear a stock market crash. But to the well-prepared investor it can present an opportunity to hunt for…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

£20,000 invested in Rolls-Royce shares ago a year ago is now worth…

Someone investing in Rolls-Royce shares a year ago would have more than doubled their money. Our writer explains why --…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

How much would an investor need in Aviva shares for a £147 monthly passive income?

Ben McPoland shows how an ISA portfolio could eventually throw off a decent amount of income each year, with help…

Read more »

Investing Articles

Should I buy Palantir stock for my ISA after its blowout Q4 earnings?

Palantir stock has lost its momentum recently. But that could be about to change after the company’s blockbuster fourth-quarter earnings.

Read more »